Evaluation of Treatment Strategies for Male Prolactin-Secreting Pituitary Neuroendocrine Tumors

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Mar 22

PMID 38516477

Authors

Norihiko Saito

Nozomi Hirai

Yuki Koyahara

Sho Sato

Yu Hiramoto

Satoshi Fujita

Haruo Nakayama

Morito Hayashi

Satoshi Iwabuchi

Affiliations

Soon will be listed here.

Abstract

Prolactin-secreting pituitary neuroendocrine tumors (PitNETs) are more common in women. Male patients may also have few symptoms and have macroadenomas extending outside the sella turcica. This study aimed to report the results of cabergoline treatment in male patients with prolactin-secreting PitNET. The study included nine male patients aged 26-65 years (median, 46 years) diagnosed with prolactin-secreting PitNETs. The age at onset, prolactin values, tumor size, symptoms, and treatment were assessed. The mean prolactin value at the initial presentation was 2734.6 ng/mL, and the mean maximum tumor diameter was 40.4 mm. Visual field disturbance was the most common symptom (44.4%), followed by headaches (33.3%), asymptomatic symptoms (11.1%), and galactorrhea (11.1%). Eight patients responded to cabergoline treatment with normalization of prolactin levels and tumor shrinkage. One patient did not respond to the cabergoline treatment and required surgical intervention. There were no cases of cerebrospinal fluid leakage. Cabergoline was found to be an effective treatment for male prolactin-secreting PitNETs.

References

Sabuncu T, Arikan E, Tasan E, Hatemi H . Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med. 2001; 40(9):857-61. DOI: 10.2169/internalmedicine.40.857. View

Di Sarno A, Landi M, Cappabianca P, Di Salle F, Rossi F, Pivonello R . Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001; 86(11):5256-61. DOI: 10.1210/jcem.86.11.8054. View

De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B . Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine. 2003; 20(1-2):75-82. DOI: 10.1385/ENDO:20:1-2:75. View

Walsh J, Pullan P . Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med. 1997; 27(4):385-90. DOI: 10.1111/j.1445-5994.1997.tb02196.x. View

Iglesias P, Bernal C, Villabona C, Castro J, Arrieta F, Diez J . Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf). 2012; 77(2):281-7. DOI: 10.1111/j.1365-2265.2012.04351.x. View

Tirosh A, Benbassat C, Lifshitz A, Shimon I . Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2014; 18(1):108-15. DOI: 10.1007/s11102-014-0563-z. View

Vroonen L, Jaffrain-Rea M, Petrossians P, Tamagno G, Chanson P, Vilar L . Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012; 167(5):651-62. DOI: 10.1530/EJE-12-0236. View

Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M . Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004; 89(4):1704-11. DOI: 10.1210/jc.2003-030979. View

Ben-Jonathan N, Hnasko R . Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001; 22(6):724-63. DOI: 10.1210/edrv.22.6.0451. View

10.

Leong K, Foy P, Swift A, Atkin S, Hadden D, MacFarlane I . CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf). 2000; 52(1):43-9. DOI: 10.1046/j.1365-2265.2000.00901.x. View

11.

Corsello S, Ubertini G, Altomare M, Lovicu R, Migneco M, Rota C . Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003; 58(5):662-70. DOI: 10.1046/j.1365-2265.2003.01770.x. View

12.

Esiri M, Bevan J, BURKE C, Adams C . Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 1986; 63(2):383-8. DOI: 10.1210/jcem-63-2-383. View

13.

Gillam M, Molitch M, Lombardi G, Colao A . Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534. DOI: 10.1210/er.2005-9998. View

14.

Duskin-Bitan H, Shimon I . Prolactinomas in males: any differences?. Pituitary. 2019; 23(1):52-57. DOI: 10.1007/s11102-019-01009-y. View

15.

Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G . PRL secreting adenomas in male patients. Pituitary. 2006; 8(1):39-42. DOI: 10.1007/s11102-005-5084-3. View

16.

Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd R, Scheithauer B . Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol. 2005; 111(1):46-52. DOI: 10.1007/s00401-005-1111-8. View

17.

Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S . Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010; 131:530-5. View

18.

Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C . Vertebral fractures in males with prolactinoma. Endocrine. 2011; 39(3):288-93. DOI: 10.1007/s12020-011-9462-5. View

19.

H Almalki M, Aljoaib N, Alotaibi M, Aldabas B, Wahedi T, Ahmad M . Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens). 2017; 16(2):139-149. DOI: 10.14310/horm.2002.1729. View

20.

Andereggen L, Frey J, Andres R, El-Koussy M, Beck J, Seiler R . Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. World Neurosurg. 2016; 97:595-602. DOI: 10.1016/j.wneu.2016.10.059. View